WO2021015515A1 - Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif - Google Patents

Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif Download PDF

Info

Publication number
WO2021015515A1
WO2021015515A1 PCT/KR2020/009533 KR2020009533W WO2021015515A1 WO 2021015515 A1 WO2021015515 A1 WO 2021015515A1 KR 2020009533 W KR2020009533 W KR 2020009533W WO 2021015515 A1 WO2021015515 A1 WO 2021015515A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture
strain
fatty liver
preventing
liver disease
Prior art date
Application number
PCT/KR2020/009533
Other languages
English (en)
Korean (ko)
Inventor
채성욱
이주영
심기석
홍성욱
노성운
이호재
Original Assignee
한국 한의학 연구원
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원, 한국식품연구원 filed Critical 한국 한의학 연구원
Publication of WO2021015515A1 publication Critical patent/WO2021015515A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the present invention relates to a composition for preventing, improving or treating fatty liver disease comprising Pediococcus inofinatus as an active ingredient.
  • liver disease in Korea is very high at 23.5 per 100,000 people, and is the number one cause of death in their 40s (41.1 people/10,000 people), the second cause of death in their 50s (72.4 people/10 million), and the third cause of death in their 30s.
  • Liver disease, accounting for (10/10,000) is a major cause of death in the middle-aged Korean population.
  • fatty liver refers to a phenomenon in which triglycerides, which are not present in normal cells, are abnormally excessively deposited in liver cells. About 5% of normal liver is composed of adipose tissue, and triglycerides, fatty acids, phospholipids, cholesterol and cholesterol esters are the main components of fat, but once fatty liver occurs, most of the components are replaced by triglycerides and the amount of triglycerides is reduced. Fatty liver is diagnosed if it is more than 5% of the weight of the liver.
  • the fatty liver deteriorates and the fat mass in the hepatocyte becomes large, the important components of the cells including the nucleus are pushed to one side and the function of the hepatocyte decreases, and the expanded hepatocytes due to the accumulated fat in the cells press the microvessels and lymph glands between the hepatocytes. Thus, the circulation of blood and lymph fluid in the liver is impaired. In this case, the liver cells cannot properly receive oxygen and nutrients, and liver function is degraded.
  • Non-alcoholic fatty liver disease is defined as a case where fatty acids accumulate more than 5% in the parenchymal cells of the liver in the form of triglycerides, not liver damage caused by alcohol. Pathologically, it is classified into simple steatosis and steatohepatitis with inflammation. If left untreated for a long time, it can lead to serious liver diseases such as hepatitis, liver fibrosis, and cirrhosis. In Korea, the incidence of non-alcoholic liver disease is also increasing due to lifestyle changes.
  • alcoholic fatty liver occurs due to excessive drinking. Although there is a difference according to genetic characteristics and sex for each individual, liver disease such as alcoholic fatty liver is likely to occur when ingesting more than 80 g of alcohol per day. Women are more likely to develop alcoholic liver disease even in smaller doses. In general, it can be calculated that about 10g of alcohol is contained in 1 soju, 1 beer, 1 Western liquor, and 1 hop of makgeolli. Most of the symptoms are asymptomatic in patients with alcoholic fatty liver, which is the mildest form, but mild tenderness in the right upper abdomen can be complained of when mild hepatic hypertrophy (the liver is larger than normal).
  • a probiotic composition including Pediococcus pentosaceus KID7 strain having a cholesterol-lowering effect is disclosed in Korean Patent No. 1673450, and Korean Patent No. 1611829 discloses obesity and obesity.
  • the Pediococcus pentosaceus CBT SL4 strain and a composition containing the same are disclosed for the prevention or treatment of metabolic diseases, the prevention, improvement or prevention of fatty liver disease comprising Pediococcus inofinatus of the present invention as an active ingredient No therapeutic composition has been disclosed.
  • the present invention is derived from the above requirements, the present invention provides a composition for the prevention, improvement or treatment of fatty liver disease comprising Pediococcus inofinatus as an active ingredient, the Pediococcus inofinatus Liver cancer cell line (HepG 2 ) has no cytotoxicity, effectively reduces the accumulation of triglycerides, reduces the content of ALT and TG in the blood in an animal model in which alcoholic fatty liver is induced, and animals in which fatty liver is induced through a high fat diet
  • the present invention was completed by confirming that the model has the effect of lowering the ALT level, reducing the liver weight, and reducing the expression level of a fat metabolism-related gene in the liver.
  • the present invention Pediococcus inopinatus ( Pediococcus inopinatus) WiKim0108 strain (Accession No: KACC 81091BP), the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture It provides a health functional food composition for preventing or improving fatty liver disease comprising at least one selected from among the active ingredients.
  • Pediococcus inopinatus WiKim0108 strain (accession number: KACC 81091BP), at least one selected from the culture of the strain, the concentrate of the culture, a dried product of the culture and an extract of the culture It provides a pharmaceutical composition for preventing or treating fatty liver disease comprising as an active ingredient.
  • Pediococcus inopinatus WiKim0108 strain (accession number: KACC 81091BP), at least one selected from the culture of the strain, the concentrate of the culture, a dried product of the culture and an extract of the culture It provides a feed additive for preventing or improving fatty liver disease comprising as an active ingredient.
  • Pediococcus inopinatus Pediococcus inopinatus
  • WiKim0108 strain accession number: KACC 81091BP
  • at least one selected from the culture of the strain the concentrate of the culture, a dried product of the culture and an extract of the culture
  • KACC 81091BP accession number: KACC 81091BP
  • the present invention relates to a composition for preventing, improving or treating fatty liver disease comprising Pediococcus inofinatus as an active ingredient, wherein Pediococcus inofinatus has no cytotoxicity in liver cancer cell line (HepG 2 ), and is neutral It has the effect of effectively reducing the accumulation of fat, lowering the blood ALT and TG content increased by alcohol, and lowering ALT levels in animal models in which fatty liver was induced through a high fat diet, reducing liver weight, and reducing fat in the liver. It has the effect of reducing the expression level of metabolic-related genes.
  • N is a normal cell without any treatment.
  • FIG. 3 is a result of treatment of the strain WiKim0108 in an animal model inducing alcoholic fatty liver and confirming the change in blood ALT content (A) and the change in TG content (B).
  • ## indicates that the blood ALT and TG content in the vehicle group was statistically significantly increased compared to the normal group, p ⁇ 0.01, and * is the Pediococcus inofinatus strain of the present invention compared to the vehicle group, or Milk C, a positive control
  • the blood ALT and TG contents in the knee treatment group were statistically significantly reduced, p ⁇ 0.05.
  • ALT and AST are indicators of liver function.
  • ## indicates that the content of ALT and AST in the blood of the high fat diet group (Veh) was statistically significantly increased compared to the normal group (N), p ⁇ 0.01.
  • * Indicates that the ALT content in the blood of the group administered with Pediococcus inofinatus strain (WiKim0108) was statistically significantly reduced compared to the high fat diet group (Veh), p ⁇ 0.05.
  • liver weight (A) and morphological change (B) after administration of Pediococcus inofinatus strain to an experimental animal ## indicates that the liver weight of the high fat diet group (Veh) was statistically significantly increased compared to the normal group (N), p ⁇ 0.01. *, ** indicates that the liver weight of the positive control group and the Pediococcus inofinatus strain (WiKim0108) administration group was statistically significantly reduced compared to the high fat diet group (Veh), * indicates p ⁇ 0.05, ** indicates p ⁇ Is 0.01.
  • CIDEC cell death-inducing DFFA-like effector C
  • the present invention is effective in one or more selected from Pediococcus inopinatus WiKim0108 strain (Accession No.: KACC 81091BP), culture of the strain, concentrate of the culture, dried product of the culture, and extract of the culture It relates to a health functional food composition for preventing or improving fatty liver disease comprising as an ingredient.
  • the Pediococcus Inofinatus WiKim0108 strain is preferably isolated from skateboard or skate kimchi, but is not limited thereto.
  • the extraction solvent of the extract of the Pediococcus inofinatus WiKim0108 strain culture is preferably water, a lower alcohol of C 1 to C 4 , or a mixture thereof, but is not limited thereto.
  • the fatty liver disease is non-alcoholic or alcoholic simple fatty liver; Non-alcoholic or alcoholic steatohepatitis; And non-alcoholic or alcoholic cirrhosis, but is not limited thereto.
  • the active ingredient is characterized by reducing the content of triglycerides in liver tissue, but is not limited thereto.
  • the active ingredient is preferably prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.
  • the strain or a culture solution thereof may be added as it is, or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method. have.
  • the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
  • the health functional food composition of the present invention may further include ingredients that are commonly added at the time of food production and are food wise acceptable.
  • ingredients that are commonly added at the time of food production and are food wise acceptable For example, when prepared as a beverage, it may further include one or more components from citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, etc. in addition to the strain of the present invention.
  • the amount that can be included as an active ingredient of the health functional food composition according to the present invention may be appropriately selected according to the age, sex, weight, condition, and symptoms of the disease of a person who wants a functional food for preventing or improving fatty liver disease It is recommended to contain about 0.01 to 10.0g per day for adults, and by ingesting foods having such a content, the effect of preventing or improving fatty liver disease can be obtained.
  • Pediococcus inopinatus Pediococcus inopinatus
  • WiKim0108 strain accession number: KACC 81091BP
  • at least one selected from the culture of the strain the concentrate of the culture, a dried product of the culture and an extract of the culture
  • KACC 81091BP accession number: KACC 81091BP
  • the pharmaceutical composition may further include at least one selected from suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions.
  • suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions.
  • the pharmaceutical compositions according to the present invention are formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to a conventional method. Can be used.
  • Carriers, excipients and diluents that can be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, Various compounds or mixtures including calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. .
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, in the strain or the endoplasmic reticulum derived from the strain. , Sucrose (sucrose) or lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
  • As a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
  • the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, and the term'pharmaceutically effective amount' of the present invention is sufficient to prevent or treat a disease at a reasonable benefit/risk ratio applicable to medical prevention or treatment. It means an amount, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion, treatment The duration, factors including drugs used in combination or co-use with the composition of the present invention used, and other factors well known in the medical field.
  • the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered single or multiple. Considering all of the above factors, it is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects.
  • the frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or divided into several doses.
  • the above dosage does not in any way limit the scope of the present invention.
  • the term "individual" of the present invention includes, without limitation, mammals including mice, livestock, humans, etc. that are likely to develop fatty liver disease.
  • the route of administration of the pharmaceutical composition may be administered through any general route as long as it can reach the target tissue.
  • the pharmaceutical composition of the present invention is not particularly limited thereto, but may be administered through a route such as oral administration or rectal administration, and in some cases, may be administered by other routes depending on the purpose.
  • the oral composition should be coated with an active agent or formulated to protect it from degradation in the stomach.
  • the composition can be administered by any device capable of moving the active substance to the target cell.
  • Pediococcus inopinatus Pediococcus inopinatus
  • WiKim0108 strain accession number: KACC 81091BP
  • at least one selected from the culture of the strain the concentrate of the culture, a dried product of the culture and an extract of the culture
  • KACC 81091BP accession number: KACC 81091BP
  • the feed additive of the present invention corresponds to an auxiliary feed in the feed management method.
  • the term'feed' may mean any natural or artificial diet, one meal meal, etc., or a component of the one meal meal for animals to eat, ingest, and digest.
  • the kind of feed is not particularly limited, and feeds commonly used in the art may be used.
  • Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, meals or grain by-products; Animal feeds such as proteins, inorganic logistics, oils and fats, minerals, oils and fats, single-cell proteins, zooplanktons or foods. These may be used alone or in combination of two or more.
  • the present invention Pediococcus inopinatus ( Pediococcus inopinatus) WiKim0108 strain (accession number: KACC 81091BP), at least one selected from the culture of the strain, the concentrate of the culture, a dried product of the culture and an extract of the culture It relates to a veterinary composition for preventing or treating fatty liver disease in animals other than humans comprising as an active ingredient.
  • liver cancer cell line (HepG 2 )
  • the liver cancer cell line (HepG 2 ) was purchased and used from ATCC (American Type Culture Collection).
  • the liver cancer cell line (HepG 2 ) was cultured in DMEM-F12 (Dulbecco's modified Eagle's medium) medium containing 10% FBS and 1% penicillin-striptomycin.
  • the cells were cultured in a 5% CO 2 incubator at 37°C, and the cultured cells were tested by dispensing a constant number of cells (1 ⁇ 10 5 cells/500 ⁇ l well) into a 24-well plate. After dispensing the cells in a 24-well plate, the cells were completely attached to the 24-well plate to form a cell shape, and the cells were used when they reached 75% confluence.
  • the 100mM palmitate and 100mM oleate stock solutions prepared in (1) above were 165 ⁇ l (1.65mM) of palmitate and 330 ⁇ l (3.3mM) of oleate, and 9,505 ⁇ l of 5% ( w/v) BSA solution was shaken while dropping and mixing (vortexing). Thereafter, it was cooled to room temperature, and then filtered through a 0.2 ⁇ m filter (the prepared mixed solution is stable even if stored at -20°C for 3 to 4 weeks).
  • the drug was orally administered to each group once a day for 12 days from the 3% alcohol diet, the normal group was administered DW for SPF, the vehicle group was administered saline, and the Pediococcus inofinatus strain (WiKim0108) was administered. Silver Pediococcus inofinatus strain was administered in an amount of 3 ⁇ 10 8 CFU per head, and the milk thistle administration group was administered with 50 mg/kg of milk thistle as a positive control.
  • the new strain used in the present invention takes skate kimchi (10g) purchased from the Skate Farming Association in Youngsanpo, Naju, Jeollanam-do, diluted with sterilized physiological saline, spread on a solid medium for separating MRS lactic acid bacteria, and incubated at 30°C for 48 hours. Different microorganisms were separated and used according to the type of colony. The isolated microorganisms were cultured at 30° C. for 48 hours in minimal nutrient medium (1% glucose, 0.5% yeast extract).
  • the skate kimchi microorganism WiKim0108 was identified through 16S ribosomal DNA gene sequence analysis. After taking the cells of the selected microorganism and washing the cells twice in sterilized physiological saline, DNA was extracted using a DNeasy tissue kit (Qiagen, Valecia, CA, USA). Universal primer for amplifying the 16S ribosomal DNA gene of the extracted DNA; 27F (5'-AGAGTTTGATCATGGCTCAG-3') (SEQ ID NO: 1) and 1492R (5'-GGATACCTTGTTACGACTT-3') (SEQ ID NO: 2) primers were used.
  • PCR reaction in 10 ⁇ l of Takara Perfect Premix (Takara, Japan) containing 0.4mM dNTP, 0.5 unit of Taq polymerase, 4mM Mg 2+ , 1 ⁇ l of DNA template (20 ⁇ g/ml), 1.0 ⁇ M forward primer 1.0 ⁇ M reverse primer was added to each 1 ⁇ l, and distilled water was added to the remainder to give a total volume of 20 ⁇ l.
  • PCR amplification was performed with a Mastercycler gradient (Eppendorf, Hamburg, Germany). The PCR reaction was performed at 95°C for 5 minutes (initial denaturation), 94°C for 45 seconds (denaturation), 52°C for 45 seconds (annealing), 72°C for 1 minute (extension), 30 cycles, and 72°C for 5 minutes. The final extension was carried out for minutes.
  • the amplified fragment of about 1400bp was transformed after binding to a T vector (Invitrogen, Carlsbad, CA, USA).
  • the new strain WiKim0108 was 97% consistent with the Pediococcus inopinatus standard strain BT (SEQ ID NO: 3). Subsequently, the new strain was named Pediococcus inopinatus WiKim0108 ( Pediococcus inopinatus WiKim0108). In addition, the Pediococcus Inofinatus WiKim0108 was deposited with the Agricultural Genetic Resource Center of the National Academy of Agricultural Sciences on March 8, 2019, and was given the deposit number KACC 81091BP.
  • the cultured HepG 2 cells were diluted by concentration for 24 hours and treated, and MTS assay (CellTiter Aqueous One Solution Cell proliferation assay kit, 3-(4,5-dimethylthiazol-2-yl)-5-(3) -carboxymethoxyphenyl)-2-(4-sulfophynyl)-2H-tetrazolium, inner salt; MTS, Promega Co.Madison, WI, USA) to determine cell viability at 490nm by microplate reader (Molecular Devices, Sunnyvale, CA, USA) It was measured as.
  • MTS assay CellTiter Aqueous One Solution Cell proliferation assay kit, 3-(4,5-dimethylthiazol-2-yl)-5-(3) -carboxymethoxyphenyl)-2-(4-sulfophynyl)-2H-tetrazolium, inner salt; MTS, Promega Co.Madison, WI, USA
  • the cell survival rate (%) when the WiKim0108 strain of the present invention was treated was approximately similar to that of the normal group (N). Therefore, it was found that the WiKim0108 strain of the present invention had little cytotoxicity.
  • liver cancer cell line HepG 2
  • the increased lipid accumulation was reduced by the treatment of the WiKim0108 strain by treating the prepared 1 mM oleate and palmitate mixture (2:1) free fatty acid.
  • the blood ALT content in the vehicle group administered with alcohol compared to the normal group was significantly increased as disclosed in FIG. 3(A)
  • the blood ALT content of the milk thistle administration group (positive control group) and the WiKim0108 administration group was significantly decreased.
  • the TG content in the blood in the vehicle group administered with alcohol compared to the normal group was increased, as disclosed in FIG.
  • the blood TG content of the WiKim0108-administered group was significantly decreased compared to the vehicle group with increased TG content.
  • mice Six-week-old male C57BL/6J mice were purified, followed by ingestion of a 60 kcal% fat diet (D12492, Research Diet, Inc) to induce non-alcoholic fatty liver. When the average body weight reached 28-29g, the WiKim0108 strain was administered orally for 10 weeks (1 ⁇ 10 8 , 1 ⁇ 10 9 CFU/mice/day), and the body weight was measured weekly, and as a positive control, milk thistle (MT, 100mg/kg/day) was administered.
  • MT milk thistle
  • the weight of the high fat diet group (HFD) increased compared to the normal group, and in contrast, the weight of the WiKim0108 strain administration group and the milk thistle administration group (MT) of the present invention decreased slightly. I did.
  • Example 5 the content of ALT and AST, which are indicators of liver function, in blood (serum) collected from the animal model by cardiac puncture was measured.
  • the ALT and AST content in the blood of the high fat diet group (Veh) compared to the normal group (N) was statistically significantly increased, and Pediococcus inofinatus compared to the high fat diet group (Veh)
  • the ALT content in the blood of the strain (WiKim0108) administration group was statistically significantly reduced.
  • Example 6 the experimental animals were sacrificed and the weight and morphological changes were confirmed after liver tissue extraction.
  • the liver weight of the high fat diet group (HFD) increased compared to the normal group, and in contrast, the liver weight of the WiKim0108 strain administration group and the milk thistle administration group (MT) of the present invention was increased. It was confirmed that there was a statistically significant decrease.
  • the morphological change of the liver was confirmed as disclosed in FIG. 6(B), and the liver of the high fat diet group (Veh) became enlarged compared to the normal group (N), and the liver of the WiKim0108 strain administration group of the present invention compared to the high fat diet group It was confirmed that the shape was similar to that of the normal group.
  • RNA was isolated from a sample of 30 mg of liver tissue obtained in Example 7, and cell death-inducing DFFA (CIDEC) related to lipid droplets involved in the regulation of fat metabolism through reverse transcription and Q-PCR using Taqman probe (ABI). -like effector C) relative mRNA expression levels were confirmed.
  • CIDEC cell death-inducing DFFA
  • the CIDEC gene expression level of the high fat diet group (Veh) was statistically significantly increased compared to the normal group (N), and the positive control group and Pediococcus inofina compared to the high fat diet group (Veh)
  • the amount of CIDEC gene expression in the group administered with the tooth strain (WiKim0108) was statistically significantly reduced.
  • Example 2 of the present invention were tested for significance between the control and the control group by performing the LSD test using the SPSS ver 20.0 program.
  • Example 3 The results obtained in Example 3 were expressed as the mean ⁇ standard error of the mean (SEM), for statistical analysis, ANOVA was performed in GraphPad Prism 8.1.2, and for post-mortem analysis, the significance was tested by performing Dunnett's multiple comparisons test.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pour prévenir, améliorer ou traiter la stéatose hépatique, la composition comprenant du Pediococcus inopinatus en tant que principe actif. Spécifiquement, le Pediococcus inopinatus ne présente pas de cytotoxicité et a également pour effet de réduire efficacement l'accumulation de graisse neutre dans une lignée cellulaire de cancer du foie (HepG2), de réduire le taux d'ALT et de TG, renforcé par l'alcool, dans le sang, d'abaisser les taux d'ALT dans un modèle animal chez lequel une stéatose hépatique a été induite par un régime riche en graisses, de réduire le poids du foie, et de réduire le niveau d'expression d'un gène associé au métabolisme des lipides dans le foie et, ainsi, la composition de la présente invention peut être utilisée utilement en tant qu'aliment fonctionnel de santé, médicament, additif alimentaire ou composition vétérinaire pour prévenir, améliorer ou traiter la stéatose hépatique.
PCT/KR2020/009533 2019-07-19 2020-07-20 Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif WO2021015515A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190087438 2019-07-19
KR10-2019-0087438 2019-07-19

Publications (1)

Publication Number Publication Date
WO2021015515A1 true WO2021015515A1 (fr) 2021-01-28

Family

ID=74192655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/009533 WO2021015515A1 (fr) 2019-07-19 2020-07-20 Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif

Country Status (2)

Country Link
KR (1) KR102406639B1 (fr)
WO (1) WO2021015515A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101617141B1 (ko) * 2015-03-03 2016-05-02 한국식품연구원 항비만 활성을 갖는 페디오코쿠스 이노피나투스
KR101660272B1 (ko) * 2009-02-27 2016-09-27 고쿠리츠다이가쿠호진 히로시마다이가쿠 비만예방 또는 개선제
KR20180049732A (ko) * 2016-11-03 2018-05-11 주식회사 쎌바이오텍 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
KR20180049731A (ko) * 2016-11-03 2018-05-11 주식회사 쎌바이오텍 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
JP2018191638A (ja) * 2017-05-18 2018-12-06 セル バイオテック カンパニー リミテッド アルコールまたはアセトアルデヒド分解用プロバイオティクスを含む組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5801802B2 (ja) 2010-06-08 2015-10-28 カルピス株式会社 脂質代謝改善剤
KR102158667B1 (ko) 2019-05-09 2020-09-22 한국 한의학 연구원 면역기능 조절 및 염증성 장질환의 개선효과를 갖는 페디오코쿠스 이노피나투스 WiKim0108 균주 및 이의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101660272B1 (ko) * 2009-02-27 2016-09-27 고쿠리츠다이가쿠호진 히로시마다이가쿠 비만예방 또는 개선제
KR101617141B1 (ko) * 2015-03-03 2016-05-02 한국식품연구원 항비만 활성을 갖는 페디오코쿠스 이노피나투스
KR20180049732A (ko) * 2016-11-03 2018-05-11 주식회사 쎌바이오텍 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
KR20180049731A (ko) * 2016-11-03 2018-05-11 주식회사 쎌바이오텍 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
JP2018191638A (ja) * 2017-05-18 2018-12-06 セル バイオテック カンパニー リミテッド アルコールまたはアセトアルデヒド分解用プロバイオティクスを含む組成物

Also Published As

Publication number Publication date
KR102406639B1 (ko) 2022-06-10
KR20210010420A (ko) 2021-01-27

Similar Documents

Publication Publication Date Title
WO2021137603A1 (fr) Souche de lactobacillus plantarum, et composition pour la prévention ou le traitement des maladies métaboliques la contenant
WO2017082611A1 (fr) Souche ayant la capacité d'inhiber l'obésité et composition pharmaceutique la contenant
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2020091166A1 (fr) Nouvelles bactéries lactiques et leur utilisation
CN112930392A (zh) 用于上呼吸道感染、压力、焦虑、记忆和认知功能障碍和衰老的益生菌
WO2021137602A1 (fr) Souche de lactobacillus fermentum, et composition pour la prévention ou le traitement de maladies métaboliques, comprenant celle-ci
WO2018043864A1 (fr) Souche de leuconostoc holzapfelii ayant pour effets de prévenir la perte des cheveux, de favoriser la pousse des cheveux ou d'améliorer la fonction sexuelle, et composition la comprenant
WO2021015514A1 (fr) Composition comprenant enterococcus lactis en tant que principe actif pour la prévention, le soulagement, ou le traitement de la stéatose hépatique
WO2018090983A9 (fr) Composé de saponine pour améliorer la microflore intestinale, son procédé de préparation et son utilisation
WO2020076043A1 (fr) Bactéries du microbiote intestinal présentant un effet prophylactique ou thérapeutique contre la dépression, et utilisation correspondante
WO2020226468A1 (fr) Souche de pediococcus inopinatus ｗikim0108 ayant un effet de régulation de la fonction immunitaire et de soulagement d'une maladie intestinale inflammatoire et son utilisation
WO2020226467A1 (fr) Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation
WO2021172900A1 (fr) Souche de lactobacillus helveticus et composition la contenant pour la prévention ou le traitement de maladies inflammatoires
WO2021015515A1 (fr) Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif
WO2020045972A1 (fr) Souche de lactobacillus fermentum mg4231 ou de lactobacillus fermentum mg4244 dérivé du corps humain, ayant une activité anti-obésité, et composition la comprenant
KR20210014605A (ko) 간 손상 예방, 개선, 또는 치료용 조성물
WO2022139489A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une stéatose hépatique alcoolique et non alcoolique
WO2019117616A1 (fr) Composition comprenant une souche d'agathobaculum sp. en tant que principe actif pour la prévention, l'atténuation ou le traitement d'un trouble du spectre autisitique
EP4356918A1 (fr) Utilisation d'une souche de lactobacillus fermentum et de lymphocytes t régulateurs en polythérapie pour la prévention et le traitement d'une maladie métabolique
WO2022260335A1 (fr) Composition pour améliorer la population microbienne intestinale comprenant du galactose
WO2023058801A1 (fr) Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409
WO2021020923A1 (fr) Composition pour prévenir, soulager ou traiter une lésion hépatique
WO2021125822A1 (fr) Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif
WO2019164197A1 (fr) Nano-vésicules dérivées de bactéries catenibacterium et utilisation associée
WO2019156335A1 (fr) Composition pharmaceutique destinée au traitement de la stéatose hépatique et aliment fonctionnel de santé destiné à l'amélioration de la fonction hépatique, les deux contenant un extrait ou une poudre de pleurotus eryngii var. ferulae en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20843088

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20843088

Country of ref document: EP

Kind code of ref document: A1